Konference: 2009 5. sympózium a workshop molekulární patologie a histo-cyto-chemie
Kategorie: Nádorová biologie/imunologie/genetika a buněčná terapie
Téma: Postery
Číslo abstraktu: p007
Autoři: RNDr. Michaela Kesselová; MUDr. Josef Srovnal, Ph.D.; Bc. Lucie Resutíková; doc. MUDr. Roman Havlík, Ph.D.; MUDr. JUDr. Dušan Klos, Ph.D., LL.M.; Věra Růžková; Mgr. Lenka Radová, Ph.D.; doc. MUDr. Marián Hajdúch, Ph.D.
Minimal residual disease (MRD) in pancreatic
carcinoma patients implies the presence of circulating tumor cells
(CTCs) in patients who have undergone curative surgery but who
remain symptom-free The CTCs can be the precursor of
micro-metastasis and relapse. The presence of MRD can be identified
in patients with poor prognosis who have minimal benefit from
surgery.
The human telomerase (hTERT) can be a potential marker for MRD detection in pancreatic carcinoma patients. Circulating/ disseminated tumor cells in the peripheral blood and bone marrow were detected using real-time RT-PCR for hTERT. The aim of this study was validation of hTERT as a diagnostic and prognostic marker for MRD detection in pancreatic carcinoma patients.
A total of 60 patients were included in the study from 2007 to 2008. All patients underwent surgery for pancreatic carcinoma. The expression of hTERT, EGFR1 (receptor for epidermal growth factor 1) and CEA (carcinoembryonic antigen) was determined in samples of peripheral and portal blood, bone marrow, peritoneal lavage and tumor tissue. We also tested the hTERT expression in 52 blood samples of healthy blood donors.
We foundthat hTERT is not a useful marker for MRD detection in pancreatic carcinoma patients because of its low tumor expression and high peripheral blood and bone marrow expression in the control group. This is probably due to the high hTERT expression in circulating blood stem and embryonic cells. We will present the relationship between hTERT expression and other clinical and pathological parameters of the disease.
This study was supported by MSM6198959216, IGA MZ CR NS 9937-4 and LC07017.
The human telomerase (hTERT) can be a potential marker for MRD detection in pancreatic carcinoma patients. Circulating/ disseminated tumor cells in the peripheral blood and bone marrow were detected using real-time RT-PCR for hTERT. The aim of this study was validation of hTERT as a diagnostic and prognostic marker for MRD detection in pancreatic carcinoma patients.
A total of 60 patients were included in the study from 2007 to 2008. All patients underwent surgery for pancreatic carcinoma. The expression of hTERT, EGFR1 (receptor for epidermal growth factor 1) and CEA (carcinoembryonic antigen) was determined in samples of peripheral and portal blood, bone marrow, peritoneal lavage and tumor tissue. We also tested the hTERT expression in 52 blood samples of healthy blood donors.
We foundthat hTERT is not a useful marker for MRD detection in pancreatic carcinoma patients because of its low tumor expression and high peripheral blood and bone marrow expression in the control group. This is probably due to the high hTERT expression in circulating blood stem and embryonic cells. We will present the relationship between hTERT expression and other clinical and pathological parameters of the disease.
This study was supported by MSM6198959216, IGA MZ CR NS 9937-4 and LC07017.
Datum přednesení příspěvku: 24. 4. 2009
